Medication and diabetic complications

A prespecified analysis of data from the DAPA-CKD trial suggests that add-on treatment with dapagliflozin slows decline in renal function among patients with chronic kidney disease irrespective of the underlying etiology.

Add-on treatment with the SGLT1 and 2 inhibitor sotagliflozin may reduce cardiovascular risk among patients with type 2 diabetes and chronic kidney disease, suggest findings from the SCORED trial published in The New England Journal of Medicine.

Listen to Sanjay Kalra, John Wilding and Lori Berard reflecting on their research highlights of this year’s virtual 56th EASD Annual Meeting (39:05). 

DAPA-CKD lead investigator Hiddo Heerspink discusses the positive outcomes of dapagliflozin treatment in people with kidney disease both with and without type 2 diabetes (8:13).

The VERTIS-CV investigators have presented further kidney outcomes data, supporting the renoprotective effects of the SGLT2 inhibitor medication class.

A meta-analysis of the DAPA-HF and EMPEROR-Reduced trials supports use of SGLT2 inhibitors in people with heart failure with or without diabetes, and suggests a positive effect on mortality endpoints.

The primary findings of the DAPA-CKD trial show that dapagliflozin significantly slows decline in kidney function in patients with chronic kidney disease irrespective of whether they have type 2 diabetes.

People with type 1 diabetes treated with multiple daily insulin injections struggle to achieve guideline-recommended targets for time in hypoglycemia while simultaneously reaching their glycated hemoglobin goals, researchers report.

Real-world study findings suggest that heart failure is associated with the greatest increase in mortality risk when compared with other cardiovascular and renal complications among people with newly diagnosed type 2 diabetes.

Among the latest findings from the DPP Outcomes Study is that long-term use of metformin does not affect the risk for cancer.